CMTA and Pharnext Enter Biomarker Research Collaboration CMT Awareness Month 2020: Be a Champion Type 2 Update: One Patient’s Diagnostic Odyssey with SORD The 2020 Summer CMTA Report Breakthrough Guide to Orthopedic Surgery for CMT CMTA Camp Footprint Has Gone Virtual for 2020 CMTA 2019 Annual Report Highlight Reel Dan Chamby Joins CMTA Board of Directors New, Potentially Treatable, Type of CMT Discovered CMT2E Gene Therapy Project Approved The 2020 Spring CMTA Report CMTA Board Approves CMT1B Project Coronavirus (COVID-19) and CMT CMTA Event Schedule Update from CEO Amy Gray Acceleron Announces Topline Results from the Phase 2 Trial of ACE-083 in Patients with Charcot-Marie-Tooth Disease Coronavirus (COVID-19) Update CMTA Funds Cutting-Edge Gene Editing Studies for Type 2 CMT The 2020 Winter CMTA Report David Coldiron Joins CMTA Board of Directors A Message from Patients to Patients Another $500,000 Pledge to Type 2 Research! The 2019 Fall CMTA Report New Gene Therapy, Type 1/Type 4 Research Projects Approved New Gene Therapy Development Program for CMT2A $1 Million Gift Pledged to CMT Type 2 Research! 2019 Summer CMTA Report Remembering Camp Footprint Finding Friendship at Camp Footprint! Support Our Campers – Whatever It Takes! Camp Help Falling in Love 2019 Spring CMTA Report CMTA Unveils Updated Logo Type 1 CMT Gene Therapy Project Now Underway A Cure for Caroline and Other CMT Stories CMTA-Funded Research Database for CMT2 Identifies New Disease-Causing Mutations A Guide to Physical and Occupational Therapy for CMT Three Major Patient Advocacy Groups Focused on CMT Research Collaborating on FDA “Voice of the Patient” Report Regenacy Pharmaceuticals Announces Collaboration with the CMTA to Advance Ricolinostat for the Treatment of Hereditary Neuropathy Volunteer Spotlight: Amy Keller How Balance Walking Can Help Fitness and Living with CMT The CMTA Announces the Funding of a New Research Study for CMT2A Breakthroughs to a Cure CMTA Announces Strategic Partnership with Acceleron to Advance CMT Treatment Options New Mobile App Simplifies Sign-Up for Patient Registry 101 Practical Tips for Dealing with CMT New CEO Takes Helm of the CMTA CMTA-Funded Study on 3-D Printing Technique for Comparing CMT Heel Surgeries Named Game Changer at AAOS Meeting Walk 4 CMT Important Alert: Neurotoxic Medication List Update CMTeen Dolphin Outing in PEOPLE Online MDA and CMTA Fund Grant to Study Gene Therapy in Charcot-Marie-Tooth Disease Invitae Announces Major Expansion of Its Neurology Test Offerings MDA and CMTA Partner to Advance Treatments and Care for Charcot-Marie-Tooth Disease NYSCF and CMTA Announce Largest-Ever Research Resource for Neuropathy Disorders STAR Launches Research for CMT4C Gilles Bouchard Takes Helm of CMTA Board CMT is on TV! PSA on Charcot-Marie-Tooth just released! The New York Stem Cell Foundation and the CMTA Enter Collaboration to Advance Neuropathies Research When you participate in the Walk 4 CMT campaign, you fund patient programs and treatment research initiatives to better the lives of the the 3 million people living with CMT. WALKS 4 CMT NEAR YOU By investing in the CMTA’s Legacy Society, you can ensure that children with CMT will grow up with the hope of a world without CMT. Plan Your Legacy Now available as a Kindle eBook for only $7.95 Order it today!